Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners began coverage on shares of Shattuck Labs (NASDAQ:STTK) in a report issued on Monday, MarketBeat reports. The brokerage issued an outperform rating and a $4.00 price objective on the stock.

Shattuck Labs Stock Performance

STTK opened at $1.19 on Monday. The business has a 50 day moving average price of $1.24 and a 200 day moving average price of $1.59. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The firm has a market cap of $56.81 million, a P/E ratio of -0.78 and a beta of 1.66.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in STTK. Zacks Investment Management acquired a new position in shares of Shattuck Labs during the fourth quarter worth approximately $25,000. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the fourth quarter worth approximately $30,000. Atom Investors LP acquired a new position in shares of Shattuck Labs during the third quarter worth approximately $35,000. Readystate Asset Management LP acquired a new position in shares of Shattuck Labs during the third quarter worth approximately $39,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Shattuck Labs during the fourth quarter worth approximately $45,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.